Citigroup Inc. initiated coverage on shares of Myovant Sciences Ltd (NASDAQ:MYOV) in a research report released on Monday. The firm issued a buy rating on the stock.

Several other brokerages have also recently commented on MYOV. JMP Securities assumed coverage on Myovant Sciences in a report on Monday. They issued an outperform rating and a $23.00 target price on the stock. Barclays PLC assumed coverage on Myovant Sciences in a report on Monday. They issued an overweight rating and a $18.00 target price on the stock. Finally, Robert W. Baird assumed coverage on Myovant Sciences in a report on Monday. They issued an outperform rating and a $20.00 target price on the stock. Five analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and a consensus target price of $20.33.

Myovant Sciences (NASDAQ:MYOV) traded up 3.75% during mid-day trading on Monday, hitting $11.63. 64,370 shares of the stock were exchanged. Myovant Sciences has a 1-year low of $10.26 and a 1-year high of $13.31. The stock has a 50 day moving average price of $11.43 and a 200 day moving average price of $11.43. The company’s market capitalization is $506.95 million.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

5 Day Chart for NASDAQ:MYOV

Receive News & Stock Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related stocks with our FREE daily email newsletter.